Erythroid responses favored luspatercept: 76.4% achieved ≥12-week transfusion independence, 25.3% remained transfusion-free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results